Full Press Release Details
BridgeBio Announces CFO Succession
PALO ALTO, Calif., March 17, 2025 (GLOBE
NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic
diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of
Principal Financial Officer and will continue to lead the Company's FP&A and accounting operations.
Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any
matters relating to the Company's operations, policies or practices. Dr. Stephenson will continue to serve as a consultant to the Company.
"It has been an immense privilege to be a part of the BridgeBio team since its inception and to help serve as many patients as possible
through our efforts. I'm proud to have helped pioneer a new type of financial model - one that makes possible broad patient service through the application of portfolio theory and use of formal NPV-driven decision-making frameworks. I look forward to
seeing the impact BridgeBio will continue to have on the industry and genetic disease patient communities," said Dr. Stephenson.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients
who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are
BridgeBio Media Contact:
Bubba Murarka, EVP Communications